IL139405A0 - Reduced particle size form of 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridyl) benzoyl] piperazine - Google Patents

Reduced particle size form of 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridyl) benzoyl] piperazine

Info

Publication number
IL139405A0
IL139405A0 IL13940599A IL13940599A IL139405A0 IL 139405 A0 IL139405 A0 IL 139405A0 IL 13940599 A IL13940599 A IL 13940599A IL 13940599 A IL13940599 A IL 13940599A IL 139405 A0 IL139405 A0 IL 139405A0
Authority
IL
Israel
Prior art keywords
chloronaphth
ylsulphonyl
piperazine
pyridyl
benzoyl
Prior art date
Application number
IL13940599A
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL139405A0 publication Critical patent/IL139405A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL13940599A 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridyl) benzoyl] piperazine IL139405A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809350.3A GB9809350D0 (en) 1998-05-02 1998-05-02 Novel salt
PCT/GB1999/001316 WO1999057112A1 (en) 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine

Publications (1)

Publication Number Publication Date
IL139405A0 true IL139405A0 (en) 2001-11-25

Family

ID=10831311

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13940599A IL139405A0 (en) 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridyl) benzoyl] piperazine

Country Status (16)

Country Link
EP (1) EP1084118A1 (en)
JP (1) JP2002513789A (en)
KR (1) KR20010043216A (en)
CN (1) CN1308629A (en)
AU (1) AU3719699A (en)
BR (1) BR9910176A (en)
CA (1) CA2331041A1 (en)
EE (1) EE200000638A (en)
GB (1) GB9809350D0 (en)
HU (1) HUP0102394A3 (en)
IL (1) IL139405A0 (en)
NO (1) NO20005498D0 (en)
PL (1) PL343705A1 (en)
SK (1) SK16522000A3 (en)
WO (1) WO1999057112A1 (en)
ZA (1) ZA200006036B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833036T2 (en) * 1997-09-30 2006-06-22 Daiichi Pharmaceutical Co., Ltd. sulfonyl
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56197C2 (en) * 1996-11-08 2003-05-15 Зенека Лімітед Heterocyclic derivatives
ATE334975T1 (en) * 1997-05-30 2006-08-15 Takeda Pharmaceutical SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE
DE69833036T2 (en) * 1997-09-30 2006-06-22 Daiichi Pharmaceutical Co., Ltd. sulfonyl

Also Published As

Publication number Publication date
SK16522000A3 (en) 2001-05-10
WO1999057112A1 (en) 1999-11-11
EE200000638A (en) 2002-04-15
HUP0102394A2 (en) 2001-12-28
HUP0102394A3 (en) 2003-01-28
ZA200006036B (en) 2002-01-25
NO20005498L (en) 2000-11-01
JP2002513789A (en) 2002-05-14
BR9910176A (en) 2001-01-09
GB9809350D0 (en) 1998-07-01
NO20005498D0 (en) 2000-11-01
CN1308629A (en) 2001-08-15
CA2331041A1 (en) 1999-11-11
EP1084118A1 (en) 2001-03-21
KR20010043216A (en) 2001-05-25
AU3719699A (en) 1999-11-23
PL343705A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
IL146707A0 (en) Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts
AU2002336462A1 (en) Piperazine and homopiperazine compounds
ES8405786A1 (en) 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
SI1252144T1 (en) Substituted glutarimides and use thereof il-12 production inhibitors
PL347635A1 (en) New piperazine and piperidine compounds
HUP0301391A3 (en) Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
EE200100498A (en) 1,4-substituted piperazine, 1,4-substituted piperidine and 1-substituted 4-alkylidenylpiperidine compounds and their therapeutic uses
HU9802129D0 (en) New piperazine and piperidine derivatives
DE69829989D1 (en) 1-(2-naphthyl) und 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazine als dopamin d4 subtype liganden
NZ299788A (en) 4-substituted(4-(1-adamantyl)phenyl) derivatives
IL139405A0 (en) Reduced particle size form of 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridyl) benzoyl] piperazine
IL121461A0 (en) Use of 1-[4-[4-aryl (or heteroaryl)-1-piperazinyl]butyl]-1H-azole derivatives
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
HUP9800511A3 (en) Phosphorylized derivatives of 4-{4-[4-(hydroxy-diphenyl)-1-pipe
NZ240261A (en) 1-(3,4-dihydro-2-oxo-1h-quinolin-6-yl)-2-(4-(2-phenylethyl)piperidin-1-yl)-ethanol or -ethanone and pharmaceutical compositions
IL143779A0 (en) Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
SI1095035T1 (en) Method for preparing 4-(3-pyridinyl)-1h-imidazole and the intermediates used
IL157061A0 (en) Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof
JPS6447776A (en) 1-(2-(phenylmethyl)phenyl)piperazine compound, manufacture and medicinal composition
AUPQ654700A0 (en) Agglomeration of alumina and binder therefor
NZ336129A (en) Micro-particulate form of a tetrahydropyridin derivative (SR 57746)
ZA952815B (en) Novel crystal forms of 1-(5-methanesulfonamidoindolyl-2-carbonyl)-4-(3-(1-methylethylamino)-2-pyridinyl) piperazine
AU6165798A (en) Non-sedating histamine antagonist compounds, compositions and methods of use thereof
NZ308110A (en) Polymorphs of lesopitron dihydrochloride, ie 2-[4-[4-[4- (chloropyrazole-1-yl)butyl]-1-piperazinyl]pyrimidine, and its hydrated forms, preparation and pharmaceutical compositions
HU9700274D0 (en) (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)-piperazin-1-yl]-phenoxy}-butiric acid as inhibitor of celle-adhesion